Lokahi Therapeutics launches Qare platform for GLP-1 medications

Lōkahi Therapeutics, a subsidiary of Glucotrack Inc. (NASDAQ: GCTK), announced Qare™, a comparative health platform designed to evaluate treatment outcomes by comparing experiences across patients using different medications within the same therapeutic class. The platform is expected to become publicly available on October 14, 2026.